Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raúl Moreno

Showing results (1-10 of 305) with videos related to

Pageof 31
Sort By:
Evidence-Based Cardiovascular Medicine|December 29, 2005
Paclitaxel-eluting stents have no greater risk of stent thrombosis in the first year than bare metal stents. CommentaryRaúl Moreno
Nature Clinical Practice. Cardiovascular Medicine|September 28, 2005
How cost-effective are sirolimus-eluting stents when compared with bare-metal stents?Raúl Moreno
Annals of Internal Medicine|February 1, 2021
After TAVI, aspirin vs. aspirin + clopidogrel for 3 mo reduced bleeding and a composite of bleeding and thrombotic events at 1 yRaúl Moreno
Revista Espanola De Cardiologia|July 19, 2005
[Drug-eluting stents and other anti-restenosis devices]Raúl Moreno
Revista Espanola De Cardiologia|April 15, 2008
[Is acute myocardial infarction an appropriate setting for drug-eluting stents?]Raúl Moreno
Revista Espanola De Cardiologia (English Ed.)|July 21, 2015
Importance of Clinical Research in Percutaneous Coronary Interventions: the Case of ThrombectomyRaúl Moreno
Annals of Internal Medicine|January 6, 2025
In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 moRaúl Moreno,
Annals of Internal Medicine|December 4, 2023
In acute MI complicated by cardiogenic shock, ECLS did not reduce 30-d all-cause mortalityRaúl Moreno
Herz|July 5, 2002
New imaging techniques in the assessment of patients with aortic stenosisRaúl Moreno, José Zamorano
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|June 25, 2005
Stent-based delivered anti-proliferative drugs in the prevention of coronary stent restenosisRaúl Moreno, Carlos Macaya
Pageof 31

Showing results (1-10 of 305) with videos related to

Sort By:
Pageof 31
Evidence-Based Cardiovascular Medicine|December 29, 2005
Paclitaxel-eluting stents have no greater risk of stent thrombosis in the first year than bare metal stents. CommentaryRaúl Moreno
Nature Clinical Practice. Cardiovascular Medicine|September 28, 2005
How cost-effective are sirolimus-eluting stents when compared with bare-metal stents?Raúl Moreno
Annals of Internal Medicine|February 1, 2021
After TAVI, aspirin vs. aspirin + clopidogrel for 3 mo reduced bleeding and a composite of bleeding and thrombotic events at 1 yRaúl Moreno
Revista Espanola De Cardiologia|July 19, 2005
[Drug-eluting stents and other anti-restenosis devices]Raúl Moreno
Revista Espanola De Cardiologia|April 15, 2008
[Is acute myocardial infarction an appropriate setting for drug-eluting stents?]Raúl Moreno
Revista Espanola De Cardiologia (English Ed.)|July 21, 2015
Importance of Clinical Research in Percutaneous Coronary Interventions: the Case of ThrombectomyRaúl Moreno
Annals of Internal Medicine|January 6, 2025
In asymptomatic severe AS, early surgery vs. conservative therapy reduced a composite of death, MI, stroke, or HF hospitalization at 63 moRaúl Moreno,
Annals of Internal Medicine|December 4, 2023
In acute MI complicated by cardiogenic shock, ECLS did not reduce 30-d all-cause mortalityRaúl Moreno
Herz|July 5, 2002
New imaging techniques in the assessment of patients with aortic stenosisRaúl Moreno, José Zamorano
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|June 25, 2005
Stent-based delivered anti-proliferative drugs in the prevention of coronary stent restenosisRaúl Moreno, Carlos Macaya
Pageof 31